From PMF to Full-Stack Scale: Kapiva Grows 6x in 3 Years, Emerges as India’s Leading Scientific Ayurveda Brand
Kapiva, India’s leading modern Ayurveda brand, has raised $60 million in Series D funding from 3one4 Capital, 360 ONE Asset, Vertex Growth Fund, and Vertex Ventures SE Asia & India. This marks a significant milestone in Kapiva’s journey to redefine preventive healthcare through science-led Ayurveda.
How Scaling Science and Building Trust Led to Series D Success
Kapiva set out to bring Ayurveda into the modern age through science, personalisation, and comprehensive execution. From its origins as a challenger brand, it has evolved into a transformative platform, leveraging clinical research, proprietary R&D, and technology-driven personalisation to deliver measurable preventive healthcare outcomes.
Its product line addresses key health needs, including diabetes care, energy, sports performance, hormonal health, and skin wellness. From Dia Free Juice to Shilajit Gold Resin and Ashwagandha Fizz Tabs, its hero offerings are setting new standards for science-led, outcome-driven wellness.
In just three years, Kapiva has turned Ayurveda into a household choice for modern wellness, scaling 6x and creating three ₹100 crore+ categories along the way. An 88 NPS and 60%+ share on marketplaces reflects the deep trust consumers have placed in the brand, while profitability across channels shows the strength of its model.
With 40,000+ offline touchpoints, a robust D2C platform, and fast-growing global presence across the U.S., UAE, and UK, Kapiva has already moved beyond promise to prove – leading Ayurveda’s modern renaissance with scale, innovation, and credibility.
Kapiva at the Forefront of Ayurveda’s Transformation
India’s Ayurveda sector, long dominated by legacy FMCG players, is now being redefined by science-led, outcome-focused brands. With rising chronic health concerns, increased demand for preventive care and growing global interest in traditional medicine, the market is projected to reach $75 billion by 2035. Consumers are actively seeking clinically validated, easy-to-use and personalised wellness solutions — a space where Kapiva has built deep trust and durable differentiation.
Kapiva’s full-stack model, spanning R&D, formulation, distribution, and digital engagement, has enabled it to scale rapidly while maintaining strong unit economics and consumer loyalty. Its 25-member R&D team, the largest at its scale, integrates best practices from pharma and FMCG to deliver outcome-driven products. The company has pioneered rapid product development, launching strategic innovations within 9 to 12 months and tactical products in under 6 months.
From Early Momentum to Market Leadership: Why 3one4 Capital Invested in Kapiva
At 3one4 Capital, we focus on empowering visionary consumer platforms with full-stack solutions, resilient unit economics, and scalable innovations. Kapiva is a testament to this ethos. Since 2020, we’ve partnered with it through significant stages of growth, supporting its journey from early momentum to market leadership.
Kapiva’s journey is marked by exceptional execution in a trust-centric category. By blending clinical expertise, product effectiveness, and a consumer-first approach, it has successfully developed three ₹100 crore-plus categories while maintaining top-tier margins and achieving unmatched customer loyalty.
As Kapiva turns centuries of Ayurvedic wisdom into a global health-tech platform, we’re excited to support the next chapter of this category-defining journey.
DISCLAIMER
The views expressed herein are those of the author as of the publication date and are subject to change without notice. Neither the author nor any of the entities under the 3one4 Capital Group have any obligation to update the content. This publications are for informational and educational purposes only and should not be construed as providing any advisory service (including financial, regulatory, or legal). It does not constitute an offer to sell or a solicitation to buy any securities or related financial instruments in any jurisdiction. Readers should perform their own due diligence and consult with relevant advisors before taking any decisions. Any reliance on the information herein is at the reader's own risk, and 3one4 Capital Group assumes no liability for any such reliance.Certain information is based on third-party sources believed to be reliable, but neither the author nor 3one4 Capital Group guarantees its accuracy, recency or completeness. There has been no independent verification of such information or the assumptions on which such information is based, unless expressly mentioned otherwise. References to specific companies, securities, or investment strategies are not endorsements. Unauthorized reproduction, distribution, or use of this document, in whole or in part, is prohibited without prior written consent from the author and/or the 3one4 Capital Group.
